Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cytosorbents ( (CTSO) ) just unveiled an announcement.
CytoSorbents Corporation held its 2025 Annual Meeting of Stockholders on June 12, 2025, where stockholders voted on several key matters. The election of five directors was confirmed, the compensation of named executive officers was approved on a non-binding basis, and the appointment of WithumSmith+Brown, PC, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s ongoing governance and operational strategies, impacting its leadership structure and financial oversight.
The most recent analyst rating on (CTSO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
Spark’s Take on CTSO Stock
According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.
The stock’s overall score reflects significant financial challenges as the most critical factor, tempered by a cautiously optimistic outlook from recent earnings guidance. Technical indicators suggest mixed short-term momentum, while valuation concerns persist due to lack of profitability.
To see Spark’s full report on CTSO stock, click here.
More about Cytosorbents
CytoSorbents Corporation operates in the medical device industry, focusing on blood purification technologies. The company is known for its CytoSorb product, which is used to treat cytokine storm and other inflammatory conditions.
Average Trading Volume: 97,828
Technical Sentiment Signal: Hold
Current Market Cap: $68.25M
Find detailed analytics on CTSO stock on TipRanks’ Stock Analysis page.